Navigation Links
United BioSource Scientist Leads Development of New Guidelines for Drug Reimbursement by German Government
Date:2/19/2008

New Methods Delivered to German Government in January

BETHESDA, Md., Feb. 19 /PRNewswire/ -- United BioSource Corporation's (UBC) director of global health economics has just delivered to the German government one of the most significant revisions of drug policy produced in Europe in more than a decade.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

The 70-page report, commissioned last year by Germany's Institute for Quality and Efficiency In Healthcare (IQWiG), will be used by the German government to evaluate drugs and devices and to set prices and reimbursement levels for those products. The document is expected to be widely influential both inside and outside of Germany, the third largest pharmaceutical market in the world.

The director and main author of the report, Jaime Caro, MD, Senior Vice President of UBC, was selected by the German government to head the eight- member international panel because of his recognized authority in the design and implementation of cutting-edge modeling and analytic techniques for health technology assessments, particularly in determining the value and safety of medical products.

According to Dr. Caro, "It was an immense honor to lead such a distinguished panel in developing pioneering methods for economic evaluation. These methods will have a strong influence on the efforts of society to control health care costs. I am very glad that with my team of experienced professionals at UBC, we can work towards improving health outcomes."

Made public in Berlin on January 24, 2008 by IQWiG, the findings and recommendations of the expert panel, if accepted, will directly impact the pricing and reimbursement of pharmaceuticals, biologicals and medical devices in Germany, which has the largest population of any EU nation.

Dr. Caro recommends that companies with marketed products and products in development set up a process to assess where the pharmaceuticals fall under the new methods and "be prepared to defend their position, understanding that they might need additional data or other strategies."

The report is titled Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System.

United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by offering expertise in science, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Western Europe (including Cologne, Germany), Eastern Europe and South America. For more information, visit http://www.unitedbiosource.com or call 866-458-1096.

CONTACT: Tess Drahzal, +1 (240) 644-0420, info@unitedbiosource.com
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jaime Caro, MD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73597


'/>"/>
SOURCE United BioSource Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
2. Davis Vision, United Concordia Free Clinic Promotes Childrens Eye and Dental Health
3. United Concordia Celebrates National Childrens Dental Health Month
4. UnitedHealthcare of the River Valley Acts to Help Tennessee Victims of Storm Devastation
5. Access Is Not Enough: What It Will Take to Transform Health Care in the United States
6. United Concordia Unveils New Online Capabilities for Producers
7. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
8. MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System
9. Peninsula United Methodist Homes Completes Enterprise-Wide Deployment of AccuNurse Voice-Assisted Care
10. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
11. United States Joins False Claims Act Cases Against Three New Jersey Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
Breaking Medicine Technology: